KR910016336A - 용액 제제 - Google Patents
용액 제제 Download PDFInfo
- Publication number
- KR910016336A KR910016336A KR1019910003135A KR910003135A KR910016336A KR 910016336 A KR910016336 A KR 910016336A KR 1019910003135 A KR1019910003135 A KR 1019910003135A KR 910003135 A KR910003135 A KR 910003135A KR 910016336 A KR910016336 A KR 910016336A
- Authority
- KR
- South Korea
- Prior art keywords
- alkyl
- represent
- pharmaceutically acceptable
- independently represent
- och
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Transplantation (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (6)
- 하기 일반식(Ⅰ)의 화합물 또는 이의 약학적으로 허용되는 염. 약학적으로 허용되는 계면 활성제 및 약학적으로 허용되는 비수용매를 함유하는 용액제제.상기식에서, 치환기[R1및 R2],[R3및 R4]및 [R5및 R6]의 각각의 근접 쌍은 독립적으로 a) 두개의 근접 수소원자를 나타내거나 b) 이들이 부착되어 있는 근접 탄소원자간에 제2결합을 형성하고; 상기 의미외에, R2는 알킬 그룹을 나타낼 수 있으며; R7은 H, OH, 보호된 하이드록시 또는 O-알킬을 나타내거나 R1과 함께 =O를 나타낼 수 있으며; R8및 R9는 독립적으로 H 또는 OH를 나타내고; R10은 H, 알킬, 하나이상의 하이드록실 그룹으로 치환된 알킬, 알케닐, 하나이상의 히이드록실 그룹으로 치환된 알케닐 또는 =O로 치환된 알킬이고; X는 0, (H, 0H),(H,H)또는 -CH2O-이고; Y는 O, (H, OH)(H, H) 또는 N-NR11R12또는 N-OR13을 나타내고; R11및 R12는 독립적으로 H, 알킬, 아릴 또는 토실을 나타내고; R13,R14,R15,R16,R17,R18,R19,R22,및 R23은 독립적으로 H 또는 알킬이고; R20및 R21은 독립적으로 0을 나타내거나 (R20a, H) 및 (R21a, H)를 각각 나타낼 수 있으며; R20a및 R21a는 독립적으로 OH, O- 알킬 또는 OCH2OCH2COH2OCH3를 나타내거나 R21a는보호된 하이드록시이고 ; 또한 R20a 및 R21a는 함께 에폭시드 고리내의 산소원자를 나타낼 수 있으며; n은 1,2 또는 3이고; 상기 의미외에, Y,R10및R23은 이들이 부착되어 있는 탄소원자와 함께 5원 또는 6원 N-, S- 또는 O-함유 복소환식 고리를 나타낼 수 있으며, 이들은 포화 또는 불포화될 수 있고, 알킬, 하이드록시, 하나이상의 하이드록실 그룹으로 치환된 알킬, O-알킬, 벤질 및 -CH2Se(C6H5)중에서 선택된 하나이상의 그룹으로 치환될 수 있다.
- 제 1 항에 있어서, 화합물(Ⅰ) 또는 이의 약학적으로 허용되는 염과 약학적으로 허용되는 계면 활성제가 1:1 내지 1:100 중량비 범위인 용액 제제.
- 제2항에 있어서, 약학적으로 허용되는 계면 활성제가 피마자유-계면 활성제인 용액 제제.
- 제3항에 있어서, 약학적으로 허용되는 비수용매가 에틸알코올인 용액제제.
- 제4항에 있어서, 화합물(Ⅰ)이 17-알릴-1, 14-디히드록시-12-[2-(4-하이드록시-3-메톡시시클로헥실)-1-메틸비닐]-23,25-디메톡시-13,19,21,27-테트라메틸-11,28-디옥사-4-아자트리시클로-[22.3.1.04.9]옥타코스-18-엔-2,3,10,16-테트라온인 용액 제제.
- 하기 일반식(Ⅰ)의 화합물 또는 이의 약학적으로 허용되는 염 및 약학적으로 허용되는 계면 활성제를 약학적으로 허용되는 비수용매중에 용해시킴을 특징으로 하여 용액 제제를 제조하는 방법;상기식에서, 치환기[R1및 R2],[R3및 R4]및[R5및 R6]의 각각의 근접 쌍은 독립적으로 a)두개의 근접 수소원자를 나타내거나 b)이들이 부착되어 있는 근접 탄소원자간에 제2결합을 형성하고; 상기 의미외에. R2는 알킬 그룹을 나타낼 수 있으며; R7은 H,OH, 보호된 하이드록시 또는 O-알킬을 나타내거나 R1과 함께 =O를 나타낼 수 있으며; R3및 R4는 독립적으로 H또는 OH를 나타내고; R10은 H, 알킬 하나이상의 하이드록실 그룹으로 치환된 알킬, 알케닐, 하나이상의 하이드록실 그룹으로 치환된 알케닐 또는 =O로 치환된 알킬이고; X는 O, (H,OH)(H,H) 또는 -CH2O-이고; Y는 O, (H,OH),(H,H)또는 N-NR11R12또는 N-OR13을 나타내고; R11및 R12는 독립적으로 H, 알킬, 아릴 또는 토실을 나타내고; R13,R14,R15,R16,R17,R18,R19,R22,및 R23은 독립적으로 H 또는 알킬이고; R20및 R21은 독립적으로 O를 나타내거나 (R20a,H)및(R21a,H)를 각각 나타낼 수 있으며; R20a및 R21a는 독립적으로 OH, O-알킬 또는 OCH2OCH2OCH2OH3를 나타내거나 R21a는 보호된 하이드록시이고; 또한 R20a및 R21a는 함께 에폭시드 고리내의 산소 원자를 나타낼 수 있으며; n은 1,2 또는 3이고; 상기 의미외에, Y,R10및R23은 이들이 부착되어 있는 탄소원자와 함께 5원 또는 6원 N-, S- 또는 O-함유 복소환식 고리를 나타낼 수 있으며, 이들은 포화 또는 불포화될 수 있고, 알킬, 하이드록시, 하나이상의 하이드록실 그룹으로 치환된 알킬 O-알킬, 벤질 및-CH2Se(C6H5)중에서 선택된 하나이상의 그룹으로 치환될 수 있다.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2-51110 | 1990-03-01 | ||
JP5111090 | 1990-03-01 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR910016336A true KR910016336A (ko) | 1991-11-05 |
KR0177158B1 KR0177158B1 (ko) | 1999-03-20 |
Family
ID=12877668
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019910003135A KR0177158B1 (ko) | 1990-03-01 | 1991-02-27 | 면역억제 활성을 갖는 트리사이클릭 화합물 함유 용액 제제 |
Country Status (20)
Country | Link |
---|---|
EP (1) | EP0444659B1 (ko) |
JP (1) | JP2522121B2 (ko) |
KR (1) | KR0177158B1 (ko) |
CN (1) | CN1028961C (ko) |
AT (1) | ATE143598T1 (ko) |
AU (1) | AU642707B2 (ko) |
CA (1) | CA2037408C (ko) |
DE (1) | DE69122418T2 (ko) |
DK (1) | DK0444659T3 (ko) |
ES (1) | ES2093650T3 (ko) |
GR (1) | GR3021777T3 (ko) |
HK (1) | HK62797A (ko) |
HU (2) | HU209436B (ko) |
IE (1) | IE75221B1 (ko) |
MX (1) | MX9203032A (ko) |
PT (1) | PT96916B (ko) |
RU (1) | RU2028142C1 (ko) |
SG (1) | SG47986A1 (ko) |
UA (1) | UA51608C2 (ko) |
ZA (1) | ZA911502B (ko) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5143918A (en) * | 1990-10-11 | 1992-09-01 | Merck & Co., Inc. | Halomacrolides and derivatives having immunosuppressive activity |
CA2054983A1 (en) * | 1990-11-08 | 1992-05-09 | Sotoo Asakura | Suspendible composition and process for preparing the same |
US5147877A (en) * | 1991-04-18 | 1992-09-15 | Merck & Co. Inc. | Semi-synthetic immunosuppressive macrolides |
US5162334A (en) * | 1991-05-13 | 1992-11-10 | Merck & Co., Inc. | Amino O-alkyl, O-alkenyl and O-alkynlmacrolides having immunosuppressive activity |
US5565560A (en) * | 1991-05-13 | 1996-10-15 | Merck & Co., Inc. | O-Aryl,O-alkyl,O-alkenyl and O-alkynylmacrolides having immunosuppressive activity |
US5189042A (en) * | 1991-08-22 | 1993-02-23 | Merck & Co. Inc. | Fluoromacrolides having immunosuppressive activity |
US5208241A (en) * | 1991-09-09 | 1993-05-04 | Merck & Co., Inc. | N-heteroaryl, n-alkylheteroaryl, n-alkenylheteroaryl and n-alkynylheteroarylmacrolides having immunosuppressive activity |
ES2148224T3 (es) * | 1992-03-30 | 2000-10-16 | American Home Prod | Formulacion de rapamicina para inyecciones intravenosas. |
AT408520B (de) * | 1993-05-27 | 2001-12-27 | Novartis Erfind Verwalt Gmbh | Galenische formulierungen |
CH686761A5 (de) * | 1993-05-27 | 1996-06-28 | Sandoz Ag | Galenische Formulierungen. |
IL111004A (en) * | 1993-09-30 | 1998-06-15 | American Home Prod | Oral formulations of rapamycin |
US5536729A (en) * | 1993-09-30 | 1996-07-16 | American Home Products Corporation | Rapamycin formulations for oral administration |
US5616588A (en) * | 1993-09-30 | 1997-04-01 | American Home Products Corporation | Rapamycin formulation for IV injection |
US5516770A (en) * | 1993-09-30 | 1996-05-14 | American Home Products Corporation | Rapamycin formulation for IV injection |
US5693648A (en) * | 1994-09-30 | 1997-12-02 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynyl-macrolides having immunosuppressive activity |
ZA9710927B (en) * | 1996-12-06 | 1998-06-15 | Fujisawa Pharmaceutical Co | Pharmaceutical composition. |
JP4903568B2 (ja) | 2003-08-29 | 2012-03-28 | ベロクシス ファーマシューティカルズ エー/エス | タクロリムスを含む固体分散体 |
PL1663217T3 (pl) | 2003-08-29 | 2010-12-31 | Lifecycle Pharma As | Stałe dyspersje zawierające takrolimus |
CN1765365B (zh) * | 2004-09-29 | 2012-01-25 | 天马药业(集团)股份有限公司 | 提高苷或苷元类药物在胃内吸收的口服软胶囊 |
KR100866728B1 (ko) * | 2004-11-12 | 2008-11-03 | 주식회사종근당 | 타크로리무스를 함유하는 주사제 |
FR2879932B1 (fr) * | 2004-12-27 | 2007-03-23 | Aventis Pharma Sa | Formulations injectable ou administrable par voie orale de derives d'azetidine |
WO2008145143A1 (en) | 2007-05-30 | 2008-12-04 | Lifecycle Pharma A/S | Once daily oral dosage form comprising tacrolimus |
CL2008000374A1 (es) | 2008-02-05 | 2008-04-04 | Igloo Zone Chile S A | Composicion farmaceutica que comprende un polvo para suspension oral de tacrolimus o una de sus sales, hidratos o solvatos y excipientes farmaceuticamente aceptables; procedimiento de preparacion de dicha composicion farmaceutica; y uso para la preve |
CN101869547B (zh) | 2009-04-24 | 2012-02-22 | 张娜 | 一种他克莫司注射制剂 |
TWI510238B (zh) | 2010-02-17 | 2015-12-01 | Lifecycle Pharma As | 穩定化他克莫司(tacrolimus)組合物 |
IL305524A (en) | 2021-03-03 | 2023-10-01 | Sana Biotechnology Inc | Immunosuppressive treatments for use with cardiomyocyte cell treatments, and associated methods and preparations |
CN115463097B (zh) * | 2021-06-11 | 2024-04-19 | 杭州中美华东制药有限公司 | 一种他克莫司缓释中间体颗粒的制备工艺 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8430455D0 (en) * | 1984-12-03 | 1985-01-09 | Fujisawa Pharmaceutical Co | Fr-900506 substance |
GB8608080D0 (en) * | 1986-04-02 | 1986-05-08 | Fujisawa Pharmaceutical Co | Solid dispersion composition |
PH26083A (en) * | 1987-11-09 | 1992-02-06 | Sandoz Ltd | 11, 28-dioxa-4-azatricyclo [22.3.1.04.9) octacos-18-ene derivatives and pharmaceutical compositions containing them and method of use thereof |
EP0350164A3 (en) * | 1988-06-13 | 1991-07-24 | Beecham Group Plc | Amphotericin derivatives |
-
1991
- 1991-02-27 KR KR1019910003135A patent/KR0177158B1/ko not_active IP Right Cessation
- 1991-02-28 SG SG1996005940A patent/SG47986A1/en unknown
- 1991-02-28 RU SU4894873/14A patent/RU2028142C1/ru active
- 1991-02-28 CN CN91101777A patent/CN1028961C/zh not_active Expired - Lifetime
- 1991-02-28 AU AU71949/91A patent/AU642707B2/en not_active Expired
- 1991-02-28 AT AT91102996T patent/ATE143598T1/de not_active IP Right Cessation
- 1991-02-28 IE IE67991A patent/IE75221B1/en not_active IP Right Cessation
- 1991-02-28 PT PT96916A patent/PT96916B/pt not_active IP Right Cessation
- 1991-02-28 EP EP91102996A patent/EP0444659B1/en not_active Expired - Lifetime
- 1991-02-28 ES ES91102996T patent/ES2093650T3/es not_active Expired - Lifetime
- 1991-02-28 UA UA4894873A patent/UA51608C2/uk unknown
- 1991-02-28 DE DE69122418T patent/DE69122418T2/de not_active Expired - Lifetime
- 1991-02-28 ZA ZA911502A patent/ZA911502B/xx unknown
- 1991-02-28 HU HU91681A patent/HU209436B/hu unknown
- 1991-02-28 DK DK91102996.5T patent/DK0444659T3/da active
- 1991-03-01 CA CA002037408A patent/CA2037408C/en not_active Expired - Lifetime
- 1991-03-01 JP JP3061146A patent/JP2522121B2/ja not_active Expired - Lifetime
-
1992
- 1992-06-19 MX MX9203032A patent/MX9203032A/es unknown
-
1995
- 1995-06-22 HU HU95P/P00341P patent/HU211502A9/hu unknown
-
1996
- 1996-11-27 GR GR960403169T patent/GR3021777T3/el unknown
-
1997
- 1997-05-08 HK HK62797A patent/HK62797A/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AU642707B2 (en) | 1993-10-28 |
MX9203032A (es) | 1992-07-31 |
HU910681D0 (en) | 1991-09-30 |
PT96916B (pt) | 1998-07-31 |
GR3021777T3 (en) | 1997-02-28 |
HK62797A (en) | 1997-05-16 |
CN1028961C (zh) | 1995-06-21 |
AU7194991A (en) | 1991-10-31 |
EP0444659A2 (en) | 1991-09-04 |
ES2093650T3 (es) | 1997-01-01 |
SG47986A1 (en) | 1998-04-17 |
HU211502A9 (en) | 1995-11-28 |
DE69122418D1 (de) | 1996-11-07 |
ZA911502B (en) | 1991-12-24 |
EP0444659A3 (en) | 1991-12-18 |
JP2522121B2 (ja) | 1996-08-07 |
CN1055110A (zh) | 1991-10-09 |
PT96916A (pt) | 1991-11-29 |
JPH04211012A (ja) | 1992-08-03 |
RU2028142C1 (ru) | 1995-02-09 |
IE910679A1 (en) | 1991-09-11 |
CA2037408C (en) | 2002-12-17 |
CA2037408A1 (en) | 1991-09-02 |
KR0177158B1 (ko) | 1999-03-20 |
HU209436B (en) | 1994-06-28 |
DK0444659T3 (da) | 1996-11-18 |
DE69122418T2 (de) | 1997-03-06 |
UA51608C2 (uk) | 2002-12-16 |
IE75221B1 (en) | 1997-08-27 |
EP0444659B1 (en) | 1996-10-02 |
ATE143598T1 (de) | 1996-10-15 |
HUT57043A (en) | 1991-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR910016336A (ko) | 용액 제제 | |
KR910002454A (ko) | 외부용 수성 액체 조성물 | |
KR920005987A (ko) | 트리사이클릭 화합물을 함유하는 연고제 | |
KR920009401A (ko) | 현탁 조성물 및 그의 제조방법 | |
RU99114776A (ru) | Лекарственные композиции | |
RU2000129665A (ru) | Фармацевтическая композиция | |
DK0669127T3 (da) | Farmaceutisk præparat med forlænget virkning | |
KR920009400A (ko) | 약제학적 조성물 | |
EP0428169B1 (en) | Aqueous liquid formulations | |
US20080207670A1 (en) | Dermally Applicable Formulations For Treating Skin Diseases in Animals | |
WO1991019495A1 (en) | Use of a macrolide compound such as fk 506 for manufacturing a medicament for treating idiopathic thrombocytopenic purpura and basedow's disease | |
KR910004647A (ko) | 마크로사이클 화합물 | |
KR960700055A (ko) | 뇌 허혈을 치료하기 위한 마크로라이드의 용도(Use of macrolides for the treatment of cerebral ischemia) | |
KR20010102370A (ko) | 리포좀 제제 | |
KR100253492B1 (ko) | 트리사이클로화합물함유 리포솜제제(liposome preparation containing tricyclic compound) | |
KR860004045A (ko) | 폴리사이클릭화합물의 제조방법 및 그 약학적 제제 | |
US5643901A (en) | Medicament for treating idiopathic thrombocytopenic purpura | |
GB2246350A (en) | Tricyclo compounds | |
RU2003137599A (ru) | Фармацевтическая композиция | |
JPH04182429A (ja) | 非水溶液製剤 | |
RU2001127531A (ru) | Липосомные препараты | |
KR890001528A (ko) | 성인 t-세포 백혈병/임파종의 억제를 위한 아바론, 아바롤 및 그 유도체의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20101116 Year of fee payment: 13 |
|
EXPY | Expiration of term |